Mutation Analysis (MutSig v2.0 and MutSigCV v0.9 merged result)
Prostate Adenocarcinoma (Primary solid tumor)
23 May 2013 | analyses__2013_05_23
Maintainer Information
Citation Information
doi:10.7908/C1BP00V8
Maintained by Dan DiCara (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2013): Mutation Analysis (MutSig v2.0 and MutSigCV v0.9 merged result). Broad Institute of MIT and Harvard. doi:10.7908/C1BP00V8
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 and MutSigCV v0.9 merged result was used to generate the results found in this report.

- Working with individual set: PRAD-TP

- Number of patients in set: 83

Input

The input for this pipeline is a set of individuals with the following files associated for each:

1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

2. A .wig file that contains information about the coverage of the sample.

Summary

- MAF used for this analysis:PRAD-TP.final_analysis_set.maf

- Significantly mutated genes (q ≤ 0.1): 0

- Mutations seen in COSMIC: 26

- Significantly mutated genes in COSMIC territory: 6

- Significantly mutated genesets: 2

Mutation Preprocessing

- Read 83 MAFs of type "Broad"

- Total number of mutations in input MAFs: 5917

- After removing 18 mutations outside chr1-24: 5899

- After removing 602 blacklisted mutations: 5297

- After removing 219 noncoding mutations: 5078

Mutation Filtering

- Number of mutations before filtering: 5078

- After removing 135 mutations outside gene set: 4943

- After removing 4 mutations outside category set: 4939

Results
Breakdown of Mutations by Type

Table 1. Get Full Table Table representing breakdown of mutations by type.

type | count
--- | ---
Frame_Shift_Del | 145
Frame_Shift_Ins | 65
In_Frame_Del | 42
In_Frame_Ins | 7
Missense_Mutation | 3041
Nonsense_Mutation | 173
Nonstop_Mutation | 2
Silent | 1368
Splice_Site | 88
Translation_Start_Site | 8
Total | 4939

Breakdown of Mutation Rates by Category Type

Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.

category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio
--- | --- | --- | --- | --- | --- | ---
*CpG->T | 816 | 138713067 | 5.9e-06 | 5.9 | 4.1 | 2.1
*Np(A/C/T)->transit | 829 | 1965699488 | 4.2e-07 | 0.42 | 0.29 | 2
*ApG->G | 94 | 381313535 | 2.5e-07 | 0.25 | 0.17 | 2.1
transver | 1310 | 2485726090 | 5.3e-07 | 0.53 | 0.37 | 5
indel+null | 519 | 2485726090 | 2.1e-07 | 0.21 | 0.15 | NaN
double_null | 3 | 2485726090 | 1.2e-09 | 0.0012 | 0.00084 | NaN
Total | 3571 | 2485726090 | 1.4e-06 | 1.4 | 1 | 3.5

Target Coverage for Each Individual

The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).

Figure 1.

Distribution of Mutation Counts, Coverage, and Mutation Rates Across Samples

Figure 2. Patients counts and rates file used to generate this plot: PRAD-TP.patients.counts_and_rates.txt

Needs description.

Figure 3. Needs description.

Figure 4. Needs description.

CoMut Plot

Figure 5. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

- N = number of sequenced bases in this gene across the individual set

- n = number of (nonsilent) mutations in this gene across the individual set

- npat = number of patients (individuals) with at least one nonsilent mutation

- nsite = number of unique sites having a non-silent mutation

- nsil = number of silent mutations in this gene across the individual set

- n1 = number of nonsilent mutations of type: *CpG->T

- n2 = number of nonsilent mutations of type: *Np(A/C/T)->transit

- n3 = number of nonsilent mutations of type: *ApG->G

- n4 = number of nonsilent mutations of type: transver

- n5 = number of nonsilent mutations of type: indel+null

- n6 = number of nonsilent mutations of type: double_null

- p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene

- p_joint = p-value for clustering + conservation

- p = p-value (overall)

- q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 0. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_cons | p_joint | p_cv | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | NKX3-1 | NK3 homeobox 1 | 43527 | 5 | 5 | 5 | 0 | 0 | 2 | 0 | 2 | 1 | 0 | 0.013 | 0.034 | 7e-05 | 0.000033 | 0.59
2 | CLSTN1 | calsyntenin 1 | 242387 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0.083 | 0.00012 | 0.33 | 0.00044 | 1
3 | YBX1 | Y box binding protein 1 | 68945 | 4 | 3 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0.0093 | 0.0026 | 0.02 | 0.00056 | 1
4 | CCNF | cyclin F | 199411 | 3 | 3 | 1 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0.034 | 0.00032 | 0.24 | 0.00078 | 1
5 | SPOP | speckle-type POZ protein | 96345 | 4 | 4 | 3 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0.32 | 0.0097 | 0.011 | 0.0011 | 1
6 | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | 122342 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 0.0021 | 0.13 | 0.0025 | 1
7 | SETD5 | SET domain containing 5 | 345156 | 4 | 1 | 4 | 1 | 0 | 3 | 0 | 1 | 0 | 0 | 0.46 | 0.00047 | 0.79 | 0.0033 | 1
8 | C1orf116 | chromosome 1 open reading frame 116 | 150780 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0.0025 | 0.002 | 0.23 | 0.0041 | 1
9 | CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | 199245 | 3 | 3 | 3 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0.3 | 0.0021 | 0.29 | 0.005 | 1
10 | SLITRK4 | SLIT and NTRK-like family, member 4 | 208728 | 3 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0.13 | 0.0082 | 0.0082 | 1
11 | DUSP27 | dual specificity phosphatase 27 (putative) | 264959 | 3 | 3 | 1 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0.94 | 0.0023 | 0.53 | 0.0093 | 1
12 | GPATCH4 | G patch domain containing 4 | 97579 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.3 | 0.075 | 0.018 | 0.01 | 1
13 | TP53 | tumor protein p53 | 105521 | 5 | 5 | 5 | 0 | 3 | 0 | 0 | 1 | 1 | 0 | 0.002 | 0.0071 | 0.24 | 0.013 | 1
14 | MMP12 | matrix metallopeptidase 12 (macrophage elastase) | 112366 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0.021 | 0.032 | 0.067 | 0.015 | 1
15 | OR2AE1 | olfactory receptor, family 2, subfamily AE, member 1 | 81008 | 2 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0.0093 | 0.051 | 0.06 | 0.021 | 1
16 | ATG10 | ATG10 autophagy related 10 homolog (S. cerevisiae) | 57021 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NaN | NaN | 0.023 | 0.023 | 1
17 | C19orf53 | chromosome 19 open reading frame 53 | 25569 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NaN | NaN | 0.024 | 0.024 | 1
18 | NKX2-4 | NK2 homeobox 4 | 23952 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NaN | NaN | 0.025 | 0.025 | 1
19 | CDKN1B | cyclin-dependent kinase inhibitor 1B (p27, Kip1) | 50142 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.52 | 1 | 0.004 | 0.026 | 1
20 | LHX3 | LIM homeobox 3 | 74497 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0.055 | 0.058 | 0.073 | 0.027 | 1
21 | ZMYM3 | zinc finger, MYM-type 3 | 288038 | 5 | 4 | 5 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0.21 | 0.4 | 0.011 | 0.028 | 1
22 | CPEB4 | cytoplasmic polyadenylation element binding protein 4 | 185085 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0.26 | 0.017 | 0.028 | 1
23 | BANF2 | barrier to autointegration factor 2 | 23572 | 2 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0.96 | 1 | 0.0045 | 0.029 | 1
24 | GNPNAT1 | glucosamine-phosphate N-acetyltransferase 1 | 47717 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NaN | NaN | 0.029 | 0.029 | 1
25 | SHFM1 | split hand/foot malformation (ectrodactyly) type 1 | 18675 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NaN | NaN | 0.029 | 0.029 | 1
26 | LCE1F | late cornified envelope 1F | 29880 | 2 | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0.46 | 0.05 | 0.1 | 0.032 | 1
27 | MLL3 | myeloid/lymphoid or mixed-lineage leukemia 3 | 1228308 | 8 | 7 | 7 | 0 | 0 | 1 | 0 | 2 | 4 | 1 | 0.78 | 0.15 | 0.035 | 0.032 | 1
28 | FOXA1 | forkhead box A1 | 92254 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.22 | 0.24 | 0.022 | 0.033 | 1
29 | ZNF485 | zinc finger protein 485 | 108980 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0.17 | 0.088 | 0.064 | 0.035 | 1
30 | TM4SF18 | transmembrane 4 L six family member 18 | 51787 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NaN | NaN | 0.035 | 0.035 | 1
31 | EPB41L4A | erythrocyte membrane protein band 4.1 like 4A | 175718 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0.026 | 0.056 | 0.11 | 0.036 | 1
32 | ATP6V1F | ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F | 30486 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | NaN | NaN | 0.037 | 0.037 | 1
33 | SOD3 | superoxide dismutase 3, extracellular | 24149 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | NaN | NaN | 0.039 | 0.039 | 1
34 | TCEB2 | transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B) | 38874 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NaN | NaN | 0.039 | 0.039 | 1
35 | ENAM | enamelin | 287223 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0.028 | 0.034 | 0.19 | 0.039 | 1

COSMIC analyses

In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.

Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 6. Number of genes displayed: 10

rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | TP53 | tumor protein p53 | 5 | 356 | 5 | 29548 | 1608 | 1.1e-09 | 5e-06
2 | CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | 3 | 138 | 3 | 11454 | 1229 | 7.3e-07 | 0.0017
3 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 3 | 767 | 3 | 63661 | 15 | 0.00012 | 0.09
4 | ACSM2B | acyl-CoA synthetase medium-chain family member 2B | 1 | 1 | 1 | 83 | 1 | 0.00012 | 0.09
5 | BRE | brain and reproductive organ-expressed (TNFRSF1A modulator) | 1 | 1 | 1 | 83 | 1 | 0.00012 | 0.09
6 | KCNH1 | potassium voltage-gated channel, subfamily H (eag-related), member 1 | 1 | 1 | 1 | 83 | 1 | 0.00012 | 0.09
7 | CHAT | choline acetyltransferase | 2 | 2 | 1 | 166 | 1 | 0.00024 | 0.13
8 | CYP4F2 | cytochrome P450, family 4, subfamily F, polypeptide 2 | 1 | 2 | 1 | 166 | 2 | 0.00024 | 0.13
9 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 2 | 220 | 2 | 18260 | 355 | 0.00034 | 0.16
10 | ACVR2A | activin A receptor, type IIA | 1 | 3 | 1 | 249 | 1 | 0.00036 | 0.16

Note:

n - number of (nonsilent) mutations in this gene across the individual set.

cos = number of unique mutated sites in this gene in COSMIC

n_cos = overlap between n and cos.

N_cos = number of individuals times cos.

cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.

p = p-value for seeing the observed amount of overlap in this gene)

q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Geneset Analyses

Table 5. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 2. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | CDKN1B(2), PRB1(2), TP53(5) | 1062488 | 9 | 9 | 9 | 0 | 3 | 1 | 0 | 2 | 3 | 0 | 0.15 | 2e-05 | 0.013
2 | P53HYPOXIAPATHWAY | Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. | ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 | 19 | ABCB1(2), AKT1(1), ATM(5), TP53(5) | 2602579 | 13 | 12 | 13 | 0 | 4 | 6 | 0 | 2 | 1 | 0 | 0.015 | 0.00016 | 0.048
3 | P53PATHWAY | p53 induces cell cycle arrest or apoptosis under conditions of DNA damage. | APAF1, ATM, BAX, BCL2, CCND1, CCNE1, CDK2, CDK4, CDKN1A, E2F1, GADD45A, MDM2, PCNA, RB1, TIMP3, TP53 | 16 | APAF1(1), ATM(5), TP53(5) | 2266716 | 11 | 10 | 11 | 0 | 3 | 5 | 0 | 2 | 1 | 0 | 0.034 | 0.0008 | 0.16
4 | TERTPATHWAY | hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. | HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 | 7 | SP1(1), TP53(5) | 879118 | 6 | 6 | 6 | 0 | 3 | 1 | 0 | 1 | 1 | 0 | 0.16 | 0.0015 | 0.23
5 | RBPATHWAY | The ATM protein kinase recognizes DNA damage and blocks cell cycle progression by phosphorylating chk1 and p53, which normally inhibits Rb to allow G1/S transitions. | ATM, CDC2, CDC25A, CDC25B, CDC25C, CDK2, CDK4, CHEK1, MYT1, RB1, TP53, WEE1, YWHAH | 12 | ATM(5), TP53(5) | 2195302 | 10 | 9 | 10 | 0 | 3 | 4 | 0 | 2 | 1 | 0 | 0.058 | 0.0019 | 0.23
6 | SA_REG_CASCADE_OF_CYCLIN_EXPR | Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases. | CCNA1, CCNA2, CCND1, CCNE1, CCNE2, CDK2, CDK4, CDKN1B, CDKN2A, E2F1, E2F2, E2F4, PRB1 | 13 | CCNA1(1), CCNE2(1), CDKN1B(2), PRB1(2) | 1130432 | 6 | 6 | 6 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 0.3 | 0.0026 | 0.25
7 | G1PATHWAY | CDK4/6-cyclin D and CDK2-cyclin E phosphorylate Rb, which allows the transcription of genes needed for the G1/S cell cycle transition. | ABL1, ATM, ATR, CCNA1, CCND1, CCNE1, CDC2, CDC25A, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, DHFR, E2F1, GSK3B, HDAC1, MADH3, MADH4, RB1, SKP2, TFDP1, TGFB1, TGFB2, TGFB3, TP53 | 25 | ATM(5), CCNA1(1), CDKN1B(2), DHFR(1), TP53(5) | 3787641 | 14 | 12 | 14 | 0 | 3 | 5 | 0 | 2 | 4 | 0 | 0.032 | 0.003 | 0.25
8 | CHEMICALPATHWAY | DNA damage promotes Bid cleavage, which stimulates mitochondrial cytochrome c release and consequent caspase activation, resulting in apoptosis. | ADPRT, AKT1, APAF1, ATM, BAD, BAX, BCL2, BCL2L1, BID, CASP3, CASP6, CASP7, CASP9, CYCS, EIF2S1, PRKCA, PRKCB1, PTK2, PXN, STAT1, TLN1, TP53 | 20 | AKT1(1), APAF1(1), ATM(5), TLN1(1), TP53(5) | 3433242 | 13 | 12 | 13 | 0 | 3 | 6 | 0 | 3 | 1 | 0 | 0.019 | 0.0032 | 0.25
9 | SMALL_LIGAND_GPCRS |  | C9orf47, CNR1, CNR2, DNMT1, EDG1, EDG2, EDG5, EDG6, MTNR1A, MTNR1B, PTAFR, PTGDR, PTGER1, PTGER2, PTGER4, PTGFR, PTGIR, TBXA2R | 13 | DNMT1(3), MTNR1A(1), PTGER2(1), TBXA2R(2) | 1410721 | 7 | 7 | 7 | 1 | 3 | 2 | 0 | 1 | 1 | 0 | 0.19 | 0.0076 | 0.44
10 | PTENPATHWAY | PTEN suppresses AKT-induced cell proliferation and antagonizes the action of PI3K. | AKT1, BCAR1, CDKN1B, FOXO3A, GRB2, ILK, ITGB1, MAPK1, MAPK3, PDK2, PDPK1, PIK3CA, PIK3R1, PTEN, PTK2, SHC1, SOS1, TNFSF6 | 16 | AKT1(1), CDKN1B(2), PIK3CA(2), PTEN(3) | 2419782 | 8 | 8 | 8 | 1 | 0 | 3 | 1 | 1 | 3 | 0 | 0.36 | 0.0076 | 0.44

Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2013 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle